Meeting
2015 ASCO Annual Meeting
DPYD c.1905+1G>A and c.2846A>T and UGT1A1*28 allelic variants as predictors of toxicity: Pharmacogenetic translational analysis from the phase III TRIBE study in metastatic colorectal cancer.
Authors
Marzia Del Re
University of Pisa Department of Clinical and Experimental Medicine, Ghezzano, Italy
Marzia Del Re , Chiara Cremolini , Fotios Loupakis , Federica Marmorino , Valentina Citi , Marta Palombi , Francesca Bergamo , Marta Schirripa , Daniele Rossini , Enrico Cortesi , Gianluca Tomasello , Rosella Spadi , Angela Buonadonna , Domenico Amoroso , Stefano Vitello , Samantha Di Donato , Cristina Granetto , Mauro D'Amico , Romano Danesi , Alfredo Falcone
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer
Citation
J Clin Oncol 33, 2015 (suppl; abstr 3532)
DOI
10.1200/jco.2015.33.15_suppl.3532
Abstract #
3532
Poster Bd #
24
Abstract Disclosures
Similar Posters
Poster
2019 Gastrointestinal Cancers Symposium
Identifying the importance of integrating routine pharmacogenomic testing for UGT1A1 and DPYD/tyms genetic variants in patients receiving irinotecan and/or 5-fluorouracil chemotherapy.
First Author: Candice Baldeo
Poster
2018 Gastrointestinal Cancers Symposium
Feasibility and value of incorporating pharmacogenomic testing for genetic variants in UGT1A1 and DPYD genes in patients receiving irinotecan and/or 5-fluorouracil chemotherapy.
First Author: Candice Baldeo
Poster
2017 Gastrointestinal Cancers Symposium
A prospective, multicenter, randomized clinical trial of UGT1A1 promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab plus FOLFIRI as the first-line setting (PURE FIST).
First Author: Jaw-Yuan Wang
Poster
2017 Gastrointestinal Cancers Symposium
A multinational, randomized, phase III trial of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab as second-line therapy for metastatic colorectal cancer: Safety analysis of Asian XELIRI project (AXEPT).
First Author: Masato Nakamura